Nymox Pharmaceutical Corp. has announced the initiation of patient enrollment for a Phase II trial of NX-1207 for the treatment of men with low-risk, localized prostate cancer. This product is already in Phase III clinical trials in Europe and the USA for the treatment of men with benign prostatic hyperplasia (BPH).
Frankly, we know very little about this product. A quick scan of a variety of web sites provided us with no detailed information about NX-1207 or how it is supposed to work. Some limited information is available in the company’s media release and there is not much more on its web site.
As of this posting, information specific to this clinical trial of NX-1207 in low-risk, localized prostate cancer has notbeen posted to the ClinicalTrials.gov web site, so we have no idea how many patients the company is seeking to enroll into this clinical trial or at what centers in the USA (or Europe) one might be able to enroll in this trial. For anyone seeking this information, we can only suggest that you contact the company by phone at 1-800 936 9669 or by e-mail at firstname.lastname@example.org.
We do know that treatment with NX-1207 requires just a single injection of the product directly into the patient’s prostate. Supposedly, this injection “does not require anaesthesia, sedation, or catheterization, takes only a few minutes and involves minimal discomfort to the patient” and “NX-1207 has thus far shown none of the adverse sexual side effects associated with approved medical and surgical treatments for BPH.”